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Background: The Hungarian national guidelines for the treatment of gonorrhoea were published in 2002 but are
now widely considered to be outdated. Improved knowledge is needed with respect to the epidemiology and
antimicrobial susceptibility of Neisseria gonorrhoeae strains currently circulating in Hungary not least for the
construction of updated local recommendations for treating gonorrhoea. European guidelines are based mostly
on western European data raising concerns locally that recommended treatments might not be optimised for the
situation in Hungary. We report our recent study on the distribution of antibiotic resistance in various Hungarian
(East European) Neisseria gonorrhoeae strains isolated from patients with gonorrhoea over the past four years.
Methods: Between January 2010 and December 2013, isolates of N. gonorrhoeae were obtained from sexually
active individuals during medical examination at the STD Center of Semmelweis University in Budapest. The
minimal inhibitory concentrations (MIC) of azithromycin, cefixime, ceftriaxone, ciprofloxacin, penicillin, tetracycline
and spectinomycin were determined to establish the antimicrobial susceptibility of the strains currently circulating
in patients that attend our clinic.
Results: Among the 9097 patients tested, 582 had an N. gonorrhoeae infection as detected by culture. The isolates
were all sensitive to ceftriaxone and spectinomycin and 581/582 strains were sensitive to cefixime. In contrast,
the number of detected strains with elevated azithromycin MIC did increase over the time period examined to
approximately 16% in 2013. There was a high percentage of detected resistance to penicillin (77%), tetracycline
(86%), and ciprofloxacin (66%) in the isolates examined in this study.
Conclusion: Current European guidelines recommend 2 g azithromycin in addition to 500 mg ceftriaxone as
first choice therapy for gonorrhoea. For the purposes of revising the Hungarian national treatment guidelines,
apparent increasing resistance to azithromycin during the last four years should be accounted for. It is also clear
that penicillin, tetracycline and ciprofloxacin are inappropriate treatment measures at least locally. We also
recommend that culture should form part of the diagnostic pathway of gonorrhoea, followed by antibiotic
susceptibility testing with MIC determination. This will provide valuable continued monitoring of antibiotic
resistance development in strains of Neisseria gonorrhoeae circulating in Hungary.
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N. gonorrhoeae infections represent 106 million of the
estimated 498 million new cases of curable sexually
transmitted infection (STI) that occur globally every
year [1]. In 2008, the World Health Organization
(WHO) estimated 3.4 million cases among adults in
the European Union (EU) [1]. Gonorrhoea remains the
second most commonly reported bacterial STI after
chlamydia infection [2]. Gonococcal infection, depend-
ing on the anatomic site of exposure can cause acute
urethritis, cervicitis, proctitis or pharyngitis. However,
most cervical, pharyngeal and rectal infections are asymp-
tomatic. Untreated or inadequately treated gonorrhoea
can cause serious reproductive complications in women.
This includes pelvic inflammatory disease, infertility and
ectopic pregnancy.
Hungary has a population of 10 million people and is
served by 135 sexual health care units that are financed
by the government. There are also more than 300 private
venerologists available to help patients with STDs. In
Hungary, gonorrhoeal infection cases must be notified to
the National Epidemiological Center regardless of whether
they were detected with nucleic acid amplification tests
(NAATs), culture or only microscopically. The notification
contains the age, gender and sexual orientation of the
patient, the anatomical sites of the infection and the
region of the country where the infection was detected.
The Hungarian national guidelines on the diagnosis
and treatment of gonorrhoea [3] were published in 2002.
These guidelines recommend 1x 250 mg ceftriaxone i.m.
or 400 mg ofloxacin per os as first choice treatment, or
400 mg cefixime per os or 500 mg ciprofloxacin per os
can be administered in cases of uncomplicated gonorrhoeal
urethritis or cervicitis. The guidelines also allow diagnosis
of gonorrhoeal urethritis in symptomatic men based
only on a Gram stain of the male urethral specimen and a
demonstration of the presence of polymorphonuclear
leukocytes with intracellular Gram-negative diplococci.
While this test is fast to administer and typically very
reliable, it limits any opportunities to monitor the
development of antibiotic resistance in N. gonorrhoeae –
a phenomenon that is causing widespread concern
globally.
In 2013, N. gonorrhoeae infections were notified in 1563
cases in Hungary [4]. However no reliable data with
respect to antimicrobial resistance (AMR) exists because
most diagnoses were based on microscopic analysis or
NAATs and did not include any culturing (which is
required for determining AMR). The National Reference
Laboratory of N. gonorrhoeae, a part of the STD Center of
Semmelweis University, receives patients and samples
from all over the country. At our centre, diagnosis of gon-
orrhoea is made by culture, meaning that AMR develop-
ment within Hungary can be monitored retrospectively.The aims of this study were therefore to investigate N.
gonorrhoeae infection rates according to gender, age and
anatomic location of the symptoms, and to determine
phenotypic AMR of the isolates obtained from patients
with gonorrhoea who visited our clinic over the previous
four years. A specific objective of the study was to
understand the appropriateness of current Hungarian
treatment recommendations especially with respect to
suspected local development of AMR in circulating N.
gonorrhoreae strains.
Methods
All studies were carried out at the STD Center of
Department of Dermatology, Venereology and Derma-
tooncology of Semmelweis University, Budapest, Hungary.
Over a four-year period (January 2010 to December
2013), N. gonorrhoeae isolates were obtained from patients
attending medical examinations for a suspected STI.
During medical examination by a physician, patient data
was also collected with respect to their age, sex, sexual
orientation and anatomic site of infection. The isolates
were cultured from consecutively symptomatic gonor-
rhoea patients and from their asymptomatic contacts. All
isolates were collected as part of standard patient care and
patients gave and signed informed consent. Patient data
was analysed according to law 1997/CLIV 26§ taking
into account maximum privacy rights and anonimity of
patients [5]. Ethical approval signed by the Semmelweis
University Regional and Institutional Committee of Science
and Research Ethics was not required for the study because
all used methods were not more than normally needed for
diagnosis and treatment.
For the identification of N. gonorrhoeae, cervical, anal,
urethral and pharyngeal swabs were taken and cultured
on preheated VCA3 agar (Biomérieux, Budapest, Hungary)
and on non-selective PVX chocolate agar (Biomérieux,
Budapest, Hungary). Cultures were incubated for 24-48
hours at a temperature of 36.5°C with 5% carbon dioxide,
and their identification and penicillinase production was
confirmed using NH-API strip tests (Biomérieux, Budapest,
Hungary).
Minimum inhibitory concentrations (MIC; mg/L) of
cefixime, ceftriaxone, penicillin, tetracycline, azithromy-
cin, spectinomycin and ciprofloxacin were determined
on PVX chocolate agar (Biomérieux, Budapest, Hungary)
using MIC strip tests (Liofilchem® s.r.l., Roseto degli
Abruzzi, Italy), according to the manufacturer’s instruc-
tions, and by using a direct colony suspension equivalent to
a 0.5 McFarland standard. Testing conditions also included
incubation at 36.5°C and 5% carbon dioxide for 24 hours.
All results were interpreted by using breakpoints for sus-
ceptibility and resistance according to the European Com-
mittee on Antimicrobial Susceptibility Testing (EUCAST)
(Table 1) [6]. To ensure the quality of the culture media
Table 1 N. gonorrhoeae MIC breakpoints for susceptibility
and resistance according to the European Committee on
Antimicrobial Susceptibility Testing (EUCAST)
Sensitive (mg/L) Resistant (mg/L)
penicillin ≤ 0,06 > 1
cefixime ≤ 0,12 > 0,12
ceftriaxone ≤ 0,12 > 0,12
ciprofloxacin ≤ 0,03 > 0,06
azithromycin ≤ 0,25 > 0,5
tetracycline ≤ 0,5 > 1
spectinomycin ≤ 64 > 64
Source: [http://www.who.int/drugresistance/
Antimicrobial_resistance_in_Neisseria_gonorrhoeae.pdf].
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used as a control strain. Isolates were classified as having a
presumed high level of resistance to tetracycline (TRNG)
if MIC was ≥16 mg/L, and as having a presumed plasmid-
mediated resistance to penicillin (PPNG) if they were ß-
lactamase positive [7].
Results
We examined the prevalence of N. gonorrhoeae infection
in 9097 sexually active patients attending the Hungarian
National STD Center between January 2010 and Decem-
ber 2013. A total of 26383 swab samples were collected
during the study period. These samples, taken from
urethra, cervix, anus, pharynx or conjunctiva were ex-
amined by culture. Over the period of the four years of
the study the number of patients who visited the STD
Center increased by 10.0% (Table 2). Depending on the
symptoms observed, gender and anamnesis, one to five
swab samples were collected for culturing. There was a
concurrent increase in the number of samples collected
of 8.7% over the study period (Table 2). The ratio of N.
gonorrhoeae positive samples to total samples collected
increased from 1.9% at the beginning of 2010 to 3.2% by
the end of 2013. The ratio of positive patients to total
patients examined increased from 5.2% in 2010 to 7.8%
by the end of 2013 (Table 2). Out of the total number of
samples collected, N. gonorrhoeae infection was confirmed
in 673 samples and 582 patients (of both sexes). This
included 16 samples taken from five patients who had
returned to the clinic with new infections.Table 2 Number of patients, samples for culture, N. gonorrho
patients at the STD Centre of Semmelweis University, 2010-2
2010
Number of patients 2167
Number of tested samples 6397
N. gonorrhoeae positive samples (Number/%) 129/1.9%
N. gonorrhoeae infected patients (Number/%) 112/5.2%In terms of total population studied the majority of
patients attending the clinic were male in all years of
the study. Specifically, the male to female ratio of patients
attending the STD Center were 62/38%, 58/42%, 57/43%
and 61/39% in 2010, 2011, 2012 and 2013 respectively.
On average over the study period 86% (498/582) of
cases examined that were subsequently determined to
be positive for N. gonorrhoeae were men, with the balance
of cases (14% (84/582)) female. 86% (96/112), 85.5%
(106/144), 84% (133/159) and 87% (163/187) were male
patients in 2010, 2011, 2012 and 2013, respectively.
Ages ranged from 14 to 76 years with an average of
31.7 years for male and 26.7 years for female patients
(Figure 1). Among the infected male patients, 19% (95/
498) declared that they were men who have sex with
men (MSM), while 81% (403/495) declared they were
heterosexual. The dominant anatomical site of gonococcal
infections was urethra in male (80%, 437/548) and cervix
in female patients (62%, 77/125). Pharyngeal and anal
infections were identified both separately and in parallel
with the dominant urethral infection in men or cervical
infection in female patients. Only one extragenital N.
gonorrhoeae infection causing conjunctivitis was detected
in a male patient, who had gonorrhoeal urethritis and
pharyngitis at the same time (Table 3).
We performed antimicrobial susceptibility tests on all
673 isolates. We found that isolates from different ana-
tomical sites of the same patients did not differ in terms
of MICs for the antibiotics we tested. Based on this
observation, calculated percentages are based on data
from single isolates (as in one strain) per patient (582
samples in total). The antimicrobial susceptibility rates
of N. gonorrhoeae to azithromycin, cefixime, ceftriaxone,
ciprofloxacin, penicillin, tetracycline and spectinomycin
are given in Table 4. Almost all isolates were susceptible to
ceftriaxone, cefixime (MIC ≤ 0.12 mg/L) and spectinomycin
(MIC ≤ 64 mg/L). However there were small increases in
the MIC averages for ceftriaxone, cefixime and spectino-
mycin between the beginning of 2010 and the end of 2013.
These were 0.002 mg/L to 0.019 mg/L for ceftriaxone,
0.016 mg/L to 0.047 mg/L for cefixime and 2 mg/L to
8 mg/L for spectinomycin. In the last case, we did identify
two isolates with an MIC of 48 mg/L. In 2013 we also
observed for the first time (in our laboratory) three
strains that exceeded breakpoints: two strains with aeae positive samples and N. gonorrhoeae infected
013
2011 2012 2013 Total
2229 2317 2384 9097
6350 6682 6954 26383
144/2.2% 178/2.7% 222/3.2% 673/2.5%
124/5.6% 159/6.9% 187/7.8% 582/6.4%
Figure 1 Distribution of N. gonorrhoeae positive patients according to their age at the time of infection between January 2010 and
December 2013.
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cefixime MIC of 0.19 mg/L. In strict accordance with
EUCAST recommendations this means 0.51% of the
strains had a cefixime MIC just above the resistant
breakpoint. Resistance to azithromycin (MIC > 0.5 mg/L)
increased from 0 to 15.86% of strains tested during the
four years of the study.
The prevalence of ciprofloxacin and tetracycline resist-
ance varied year to year but was consistently high for
both antibiotics (66% and 86%, respectively) (see Table 4).
The prevalence of penicillin resistance appeared to
slowly increase from 75 to 79% in the four years of the
study. PPNG was detected in 16.2% of the isolates andTable 3 Distribution of specimens cultured for N.
gonorrhoeae strains between January 2010 and
December 2013
Samples Men % Women %
Cervix 0 0 77 61.6
Pharynx 22 4.0 11 8.8
Anus 88 16.1 10 8.0
Urethra 437 79.7 27 21.6
Conjunctiva 1 0.2 0 0
Total 548 100 125 100TRNG in 23%, whereas 14.8% of the isolates presented
both phenotypes (PPNG/TRNG).
Discussion
In Hungary, as is the case in many other countries, the
control of gonococcal infections mostly relies on an
effective single-dose antibiotic therapy given at the first
clinical presentation of the patient. Prior knowledge of the
antimicrobial susceptibility pattern of the particular strain
infecting the patient is routinely not established however.
With increasing evidence of antimicrobial resistance in
gonococcal infections there is therefore a real risk of
treatment failure and development of further resistanceTable 4 Distribution of antibiotic resistant N. gonorrhoeae
strains (%) in Hungary
Resistance to antibiotics/year 2010 2011 2012 2013
Azithromycin 0 0.8 6.9 15.9
Cefixime 0 0 0 0.2
Ceftriaxone 0 0 0 0
Ciprofloxacin 70.5 61.7 64.6 67.2
Penicillin 75.4 76.2 77.3 79.5
Spectinomycin 0 0 0 0
Tetracycline 88.1 87.5 82.9 85.5
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diagnosis and treatment of gonorrhoea date from 2002
and are based on bygone national and international
data of gonococcal resistance. Our study therefore
sought to understand ongoing resistance trends with
respect to gonorrhoea in Hungary, and to ultimately
contribute to the preparation of new guidelines to ensure
the success of any therapies targeting gonorrhoea. Our
data, based on sampling over the previous four years
highlight that there appears to be continued antimicro-
bial resistance in circulating strains of N. gonorrhoeae
strains to a variety of common antibiotics (including
high rates of resistance to ciprofloxacin, which is one of
the antibiotics recommended in the national Hungarian
guidelines) and that there may be developing resistance to
others (including azithromycin and penicillin and possibly
even cefixime) in this part of eastern Europe.
Over the last 70–80 years treatment options have dimin-
ished due to the emergence and spread of resistance to all
drugs recommended for treatment of gonorrhoea. Plasmid-
mediated resistance mechanisms have been described for
penicillins (PPNG) and tetracyclines (TRNG), but not for
sulphonamides, macrolides, spectinomycin, aminogly-
cosides, quinolones and cephalosporines. In these cases
only chromosomal mutations have been described as
the reason for resistance [8]. Since N. gonorrhoeae is
naturally competent for the uptake and recombination
of external DNA during its entire life cycle, the transfer
of chromosomally encoded resistance genes is both
rapid and extensive in comparison to uptake of plasmid-
mediated resistance genes [9]. Resistance may initially
emerge in the commensal Neisseria spp. inhabiting the
human body as these are exposed more frequently to
antimicrobials than the transiently acquired gonococci.
The commensal Neisseria spp. can act as a reservoir of
resistance genes that can be transferred to gonococci
through transformation. In our study N. gonorrhoeae
was detected in pharyngeal swab samples of symptomatic
or asymptomatic infected patients in 4 and 8% of male
and female patients, respectively. This may be significant
as the pharynx may be an ideal anatomic site to provide
the opportunity for chromosomally encoded resistance
development. Pharyngeal gonorrhoea is mostly asymp-
tomatic meaning that commensal Neisseria spp. and N.
gonorrhoeae can co-exist for extended time periods in
the pharynx and share genetic material [10-12]. This is
likely to include the transfer of antibiotic resistance genes
and therefore the development of antibiotic resistance in
N. gonorrhoeae. As humans appear to be the obligate
host of N. gonorrhoeae it would appear that control of
resistance lies in appropriate treatment regimes and
that includes correct usage of antibiotics. The emergence
and spread of antimicrobial resistance in N. gonorrhoeae
all over the world requires the control of incidence ofgonorrhoea through education and appropriate sexual
practices and control of antimicrobial resistance through
appropriate antibiotic usage. This is particularly the case
in Hungary where both incidence of gonorrhoea and anti-
biotic resistance appear to be increasing in recent years.
According to data from the National Epidemiological
Center the incidence of N. gonorrhoeae infection appears
to be increasing in Hungary - the number of the reported
(notified) cases was 1158 in 2010, 1369 in 2011, 1491 in
2012 and 1563 in 2013 [4]. In the report of the National
Epidemiological Center, 75-82% of the infections were
detected in male patients and the dominant site of infec-
tion was urethra in male (81%), and cervix in female
(62%) (in this time period in Hungary). About 10% of
the notifiable infections were diagnosed at the STD
Center of Semmelweis University during this period,
and the distribution according to gender, age and location
of the symptoms was the same as the national results.
To our knowledge the only available data relating to
the distribution of resistance against different antibiotics
of the Hungarian N. gonorrhoeae strains exist in the sur-
veillance reports of EURO-GASP (European Gonococcal
Antimicrobial Surveillance Programme) [13,14]. In these
projects 14 and 13N. gonorrhoeae strains were collected
from Hungary in 2010 and 2011. These data were col-
lected from a sentinel laboratory based on the report of
a selected group of physicians [13,14]. In these reports
there were no Hungarian N. gonorrhoeae strains with
PPNG property. All these strains were susceptible to
azithromycin, and 79% or 61.5% were resistant to ciproflox-
acin in 2010 and 2011, respectively. These data contained
no occurrence of cefixime resistant strains in 2010, but
1% of the isolates had decreased susceptibility to cefixime
in 2011.
In our work we processed 582N. gonorrhoeae strains,
which corresponds to approximately 10% of the total
number of notified infections in Hungary during the
period between the beginning of 2010 and the end of
2013. This provides a more representative assessment of
antimicrobial resistance to N. gonorrhoeae than any other
previous survey carried out in Hungary.
Among our 582N. gonorrhoeae isolates generally no
resistance occurred against ceftriaxone, cefixime and
spectinomycin. These results were interpreted using
breakpoints for susceptibility and resistance according to
the EUCAST [6]. All the measured MICs were not
higher than their respective resistance breakpoints, with
the exception of three strains isolated in 2013, which
showed slightly raised resistance towards cefixime. Year
on year there was a small increase in MIC averages for
ceftriaxone, cefixime and spectinomycin. These averages
did not exceed resistance breakpoints with the exception
of the three cases mentioned above. We also found a
small increase in the number of penicillin resistant
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was stable at around 16%, which suggests different
chromosomal mutations may be reasonably assumed for
this type of resistance development. The acquisition of a
mosaic penA gene encoding a remodelled penicillin bind-
ing protein (PBP2) and overproduction of an efflux pump
in N. gonorrhoeae appears to be responsible for reduced
susceptibility to cephalosporins [15]. Since the first ceftri-
axone-resistant isolates were identified in Japan (2009),
France (2010), and Spain (2011) [16-18], a real threat now
exists that extensively resistant strains of N. gonorrhoeae
may emerge and spread worldwide. Enhanced surveillance
for resistance against other anti-gonococcal agents is
therefore warranted.
According to the EUCAST interpretations all of the
strains were susceptible to spectinomycin with a MIC
lower than 64 mg/L. The average spectinomycin MIC
increased during the study period and we did identify two
isolates with clearly elevated (48 mg/L) MICs, suggesting
that only intermediate sensitivity can be assured (accord-
ing to the recommendation of Clinical and Laboratory
Standards Institute (CLSI) [19]). Verified resistance to
spectinomycin is exceedingly rare worldwide with only
five spectinomycin-resistant isolates (all between 1988
and 1990) identified in the US Gonococcal Isolate Sur-
veillance Project [20] using the CLSI recommendation.
In comparison no spectinomycin-resistant isolates have
been identified in the EURO-GASP in 2010-2011 [13,14].
The very common occurrence (82-88% in Hungary over
the past four years in our study) of tetracycline resistant
strains is not unique in comparison to other countries.
Despite some exceptions (in the USA, tetracycline
resistance rates are only 22.5% [21] while rates in South
America and the Caribbean decreased from a level of
61.1% of isolates tested in 2001 to 21.8% in 2010 [22]),
high prevalence of tetracycline resistance has been
detected in some countries in South East Asia. Bhutan
and Indonesia reported a resistance rate of more than
95% between 2009 and 2012 [23], and a rate of 92.8%
tetracycline resistance was noted in North Africa in
2009 [24]. This high percentage of detected resistance
to tetracycline indicates that this antibiotic is certainly
not appropriate for gonorrhoea treatment in Hungary
and probably elsewhere.
Furthermore, the effectiveness of the quinolone antibi-
otics appears to be equally limited. For example, the
prevalence of ciprofloxacin resistant strains that we
detected in this study was between 61-70% over the
previous four years. In comparison, prevalence of cip-
rofloxacin resistance in the USA was 13.5% [21], while
in Latin America and the Caribbean ciprofloxacin
rates increased from 1.6% of isolates tested in 1997 to
42.1% in 2010 [21]. Rates of ciprofloxacin resistance have
decreased continuously since 2009 in the participantcountries of EURO-GASP, but still remained as high as
52.7% and 48.7% in 2010 and 2011, respectively [13,14].
The usage of ciprofloxacin, which was previously recom-
mended in gonorrhoea treatment in Hungary, is no longer
suitable according to the rates of resistance we observed
in recent years.
Resistance to azithromycin (MIC > 0.5 mg/L) increased
from 0 to 15.86% during the four years of our study.
The Centers for Disease Control and Prevention [25]
and the International Union against Sexually Transmitted
Infections (IUSTI) [26] published global and European
guidelines for diagnosis and/or treatment of N. gonorrhoeae
to combat and mitigate the spread of multidrug-resistant
gonorrhoea. Their new treatment guidelines revised the
recommended treatment to be 250 mg or 500 mg ceftri-
axone im combined with 1 g or 2 g azithromycin per os,
respectively. However, based on past and current data
reported in this study, N. gonorrhoeae may continue to
emerge with azithromycin resistance in our country,
especially as increased usage of this antibiotic is expected.
The World Health Organization has suggested that an
antimicrobial should not be used when >5% of strains
demonstrate resistance [27]. If our data can be verified it
would appear that this cut-off has already been passed
in Hungary. In addition to complying with the new rec-
ommendations it is necessary to also adequately run
antimicrobial surveillance programmes. It would be
advisable to now include surveillance for ceftriaxone
and azithromycin resistance, not least to control the
emergence of extremely drug resistant strains.
Conclusion
Our study contributes large amounts of data on the
current antimicrobial susceptibility rates of circulating
N. gonorrhoeae strains in Hungary in the period between
the beginning of 2010 and up to the end of 2013. It is
clear that there are considerable levels of antimicrobial
resistance in circulating strains and in some cases resist-
ance may be emerging. Of concern is that such resistance
may be emerging towards antibiotics that are currently
recommended as first line treatments for gonorrhoea in
Hungary. Current diagnosis approaches typically only
utilise Gram staining techniques, which while regarded
as highly accurate, do not allow antibiotic resistance to
be monitored routinely. Based on our observations we
are now of the opinion that culture and susceptibility
testing are indispensable in the currently developing
situation of multidrug resistance among the N. gonorrhoeae
strains. It is somewhat reassuring that during the previous
four years, resistance has not been identified towards the
recommended treatment of ceftriaxone in Hungary. How-
ever, in Europe extensively drug resistant N. gonorrhoeae
strains have emerged and we believe it is only a matter of
time before this occurs in Hungary if appropriate control
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emergence of resistance should prompt revision of our
national diagnosis and treatment guidelines. The recom-
mendations of IUSTI and other international organisations
involved in developing advice and treatment approaches for
gonorrhoea should be considered. However in Hungary
the incidence of azithromycin resistance appears to
have increased over recent years and this should be
taken into account in developing any new guidelines.
Abbreviations
AMR: Antimicrobial resistance; CLSI: Clinical and laboratory standards
institute; EUCAST: European committee on antimicrobial susceptibility
testing; EURO-GASP: European gonococcal antimicrobial surveillance
programme; IUSTI: International union against sexually transmitted infections;
MIC: Minimal inhibitory concentrations; MSM: Men who have sex with men;
PBP: Penicillin binding protein; PPNG: Penicillinase producing Neisseria
gonorrhoeae; TRNG: Tetracycline resistant Neisseria gonorrhoeae.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
BA, NNE collected the retrospective data. OE wrote the manuscript. BA, NNE, MN
and OE conducted the review of the literature relevant to the paper. MN, MM and
SK examined and treated the patients. BA, NNE and OE performed identification
and susceptibility testing of the strains. All authors contributed suggestions to the
manuscript. All authors read and approved the final manuscript.
Acknowledgements
We would like to acknowledge the technical assistance of Ildikó Bencze
Győriné and Elvira Vörös. We would also like to thank Max Bingham, PhD
(freelance editor, Rotterdam, The Netherlands) for technical writing and
editorial assistance prior to submission.
Received: 12 March 2014 Accepted: 30 July 2014
Published: 6 August 2014
References
1. World Health Organization (WHO), Department of Reproductive Health and
Research: Global action Plan to Control the Spread and Impact of
Antimicrobial Resistance in Neisseria Gonorrhoeae. In Geneva: WHO;
2012:1–36 [http://www.who.int/reproductivehealth/publications/rtis/
9789241503501/en/]. ISBN 978 92 4 150350 1.
2. European Centre for Disease Prevention and Control (ECDC): Response Plan
to Control and Manage the Threat of Multi-Drug Resistant Gonorrhoea
in Europe. In Stockholm: ECDC; 2012:1–23. doi:10.2900/60053 [http://www.
ecdc.europa.eu/en/publications/publications/1206-ecdc-mdr-gonorrhoea-
response-plan.pdf]. ISBN 978 92 9193 375 4.
3. Bőr- és Nemi Betegségek Szakmai Kollégiuma/ Skin and Venereal Diseases
Professional College: Módszertani ajánlás a szexuális úton terjedő infekciók
kivizsgálására és kezelésére/ Methodological letter of detection of sexually
transmitted infections and treatment. Egészségügyi Közlöny/Health Bulletin
2002, 52:1509–1518 [http://www.otszonline.hu/cikk/modszertani_ajanlas_
a_szexualis_uton_terjedo_infekciok_kivizsgalasara_es_kezelesere]
4. Országos Epidemiológiai Központ (OEK)/ National Epidemiological Center:
Szexuális úton terjedő betegségek Magyarországon/Sexually transmitted
diseases in Hungary 2013. IV. Epinfo 2014, 5:45–50 [www.oek.hu/oekfile.pl?
fid=3813]
5. Magyar Országgyűlés/ Parlament of Hungary: Hatályos jogszabályok
gyüjteménye /Collection of existing legislation. [http://net.jogtar.hu/jr/
gen/hjegy_doc.cgi?docid=99700154.TV]
6. The European Committee on Antimicrobial Susceptibility Testing:
Breakpoint Tables for Interpretation of MICs and Zone Diameters. 2014
[http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/
Breakpoint_tables/Breakpoint_table_v_4.0.pdf]
7. Tapsall JW: Antibiotic resistance in Neisseria gonorrhoeae. Clin Infect Dis
2005, 41(Supplement 4):S263–S268. doi:10.1086/430787.8. Lewis DA, Lukehart SA: Antimicrobial resistance in Neisseria gonorrhoeae
and Treponema pallidum: evolution, therapeutic challenges and the need
to strengthen global surveillance. Sex Transm Infect 2011, 87:ii39–ii43.
doi:10.1136/sti.2010.047712.
9. Unemo M, Shafer WM: Antibiotic resistance in Neisseria gonorrhoeae:
origin, evolution, and lessons learned for the future. Ann NY Acad Sci
2011, 1230:E19–E28. doi:10.1111/j.1749-6632.2011.06215.x.
10. Unemo M, Nicholas RA: Emergence of multidrug-resistant, extensively
drug-resistant and untreatable gonorrhea. Future Microbiol 2012,
7:1401–1422. doi:10.2217/fmb.12.117.
11. Furuya R, Onoye Y, Kanayama A, Saika T, Iyoda T, Tatewaki M, Matsuzaki K,
Kobayashi I, Tanaka M: Antimicrobial resistance in clinical isolates of
Neisseria subflava from the oral cavities of a Japanese population.
J Infect Chemother 2007, 13:302–304. doi:10.1007/s10156-007-0541-8.
12. Saika T, Nishiyama T, Kanayama A, Kobayashi I, Nakayama H, Tanaka M,
Naito S: Comparison of Neisseria gonorrhoeae isolates from the genital
tract and pharynx of two gonorrhea patients. J Infect Chemother 2001,
7:175–179. doi:10.1007/s101560100031.
13. European Centre for Disease Prevention and Control: Gonococcal
Antimicrobial Susceptibility Surveillance in Europe — 2010. 2012. [http://ecdc.
europa.eu/en/publications/Publications/1206-Gonococcal-AMR.pdf]
(Accessed 18 Apr 2013).
14. European Centre for Disease Prevention and Control: Gonococcal
Antimicrobial Susceptibility Surveillance in Europe 2011. 2013. [http://ecdc.
europa.eu/en/publications/Publications/gonococcal-antimicrobial-
susceptibility-surveillance-27-mar 2013.pdf] (accessed 18 Apr 2013).
15. Ito M, Deguchi T, Mizutani KS, Yasuda M, Yokoi S, Ito S, Takahashi Y, Ishihara S,
Kawamura Y, Ezaki T: Emergence and spread of Neisseria gonorrhoeae
clinical isolates harboring mosaic-like structure of penicillin-binding protein
2 in Central Japan. Antimicrob Agents Chemother 2005, 49:137–143.
doi:10.1128/AAC.49.1.137-143.2005.
16. Ohnishi M, Golparian D, Shimuta K, Saika T, Hoshina S, Iwasaku K, Nakayama
S, Kitawaki J, Unemo M: Is Neisseria gonorrhoeae initiating a future era of
untreatable gonorrhea? Detailed characterization of the first strain with
high-level resistance to ceftriaxone. Antimicrob Agents Chemother 2011,
55:3538–3545. doi:10.1128/AAC.00325-11.
17. Unemo M, Golparian D, Nicholas R, Ohnishi M, Gallay A, Sednaoui P:
High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in
France: novel penA mosaic allele in a successful international clone
causes treatment failure. Antimicrob Agents Chemother 2012, 56:1273–1280.
doi:10.1128/AAC.05760-11.
18. Cámara J, Serra J, Ayats J, Bastida T, Carnicer-Pont D, Andreu A, Ardanuy C:
Molecular characterization of two high-level ceftriaxone-resistant Neisseria
gonorrhoeae isolates detected in Catalonia, Spain. J Antimicrob Chemother
2012, 67:1858–1860. doi:10.1093/jac/dks162.
19. Clinical and Laboratory Standards Institute: Performance Standards for
Antimicrobial Susceptibility Testing; Twenty-First Informational Supplement.
CLSI Document M100-S21 (ISBN 1-56238-742-1). 940 West Valley Road, Suite
1400, Wayne, Pennsylvania 19087 USA: Clinical and Laboratory Standards
Institute; 2011.
20. Gorwitz RJ, Nakashima AK, Moran JS, Knapp JS: Sentinel Surveillance for
Antimicrobial Resistance in Neisseria gonorrhoeae - United States, 1988-
1991: the gonococcal isolate surveillance project study group. MMWR
CDC Surveill Summ 1993, 42:29–39 [http://www.cdc.gov/mmwr/preview/
mmwrhtml/00021562.htm]
21. Kirkcaldy RD, Kidd S, Weinstock HS, Papp JR, Bolan GA: Trends in
antimicrobial resistance in Neisseria gonorrhoeae in the USA: the
Gonococcal Isolate Surveillance Project (GISP), January 2006-June 2012.
Sex Transm Infect 2013, 89:5–10. doi:10.1136/sextrans-2012-050472.
22. Dillon JA, Trecker MA, Thakur SD: Gonococcal Antimicrobial Surveillance
Program Network in Latin America and Caribbean 1990-2011: two
decades of the gonococcal antimicrobial surveillance program in South
America and the Caribbean: challenges and opportunities. Sex Transm
Infect 2013, 89:36–41. doi:10.1136/sextrans-2012-050905.
23. Bala M, Kakran M, Singh V, Sood S, Ramesh V: Monitoring antimicrobial
resistance in Neisseria gonorrhoeae in selected countries of the WHO
South-East Asia Region between 2009 and 2012: a retrospective analysis.
Sex Transm Infect 2013, 89:28–35. doi:10.1136/sextrans-2012-050904.
24. Hançali A, Ndowa F, Bellaji B, Bennani A, Kettani A, Charof R, El Aouad R:
Antimicrobial resistance monitoring in Neisseria gonorrhoeae and
strategic use of funds from the Global Fund to set up a systematic
Brunner et al. BMC Infectious Diseases 2014, 14:433 Page 8 of 8
http://www.biomedcentral.com/1471-2334/14/433Moroccan gonococcal antimicrobial surveillance programme. Sex Transm
Infect 2013, 89:24–27. doi:10.1136/sextrans-2013-051166.
25. Workowsky KA, Berman S, Centers for Disease Control and Prevention (CDC):
Sexually transmitted diseases treatment guidelines 2010. MMWR Recomm
Rep 2010, 59:1–116.
26. Bignell C, Unemo M, European STI, Board GE: European guideline on the
diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS 2012,
2013(24):85–92.
27. Tapsall J: Antimicrobial Resistance in Neisseria gonorrhoeae. Geneva,
Switzerland: World Health Organization; 2001:1–58.
doi:10.1186/1471-2334-14-433
Cite this article as: Brunner et al.: Incidence and antimicrobial susceptibility
of Neisseria gonorrhoeae isolates from patients attending the national
Neisseria gonorrhoeae reference laboratory of Hungary. BMC Infectious
Diseases 2014 14:433.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
